Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.

Actor portrayal.

Commercially insured patients may pay as little as $0 per year for once-weekly NGENLA.

Commercially insured patients may pay as little as $0 per year for once-weekly NGENLA.
NGENLA Copay Program

Financial support for patients is available. One simple plan covers copays and deductibles. Plus, patients are automatically re-enrolled January 1 of each year.

Eligibility required. Annual savings up to $1,000 - $8,000. State and federal beneficiaries not eligible. Terms and conditions apply; see below.

Need help while waiting for insurance to approve NGENLA? We’ve got you covered.

If your NGENLA prior authorization is delayed or denied, the NGENLA Interim Care Program may be able to provide you with up to 90 days of free NGENLA while your healthcare provider works to appeal the decision.*†

How it works:

  • Your doctor requests Interim Care for you through the Pfizer Bridge Program.

  • If you qualify, you’ll get NGENLA free for 30 to 90 days.

Questions? We’re here for you.

Call the Pfizer Bridge Program at 1-800-645-1280 for details.

Terms and conditions apply.

Interim Care must be requested by your healthcare provider. Patients must meet program criteria to receive the support. Interim Care support can range from 30 days to a maximum of 90 days depending on the type of coverage delay. For FDA-approved indications only. Commercially insured patients only and may not reside in Massachusetts or Michigan.

 Interim Care is not health insurance and is available for eligible, commercially insured patients only. Offer is only available to patients who have been diagnosed with an FDA-approved indication for NGENLA. For patients who experience a delay in insurance coverage while actively pursuing a prior authorization or appeal, coverage may be up to a maximum of 90 days. Interim Care is not available to patients covered under Medicaid, Medicare, or other federal or state healthcare insurance programs.

NGENLA has the broadest preferred commercial coverage in the US of any once-weekly pediatric growth hormone treatment.

TERMS AND CONDITIONS

By using this offer for the NGENLA Copay Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • Eligible patients with commercial prescription drug insurance coverage for NGENLA may pay as little $0 per prescription fill. Patient out of pocket expense will vary. The value of this offer is limited to annual benefit of $1,000-$8,000. Once a patient reaches the annual maximum benefit, patient is responsible for paying the remaining monthly out of pocket costs.
  • Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patients must have private insurance. Offer is not valid for cash paying patients.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the NGENLA Copay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the NGENLA Copay Card as may be required. You should not use the NGENLA Copay Card if your insurer or health plan prohibits use of manufacturer copay cards.
  • This copay card is not valid where prohibited by law.
  • The benefit under the NGENLA Copay Program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Third party payers, pharmacy benefit managers, or the agents of either are prohibited from assisting patients with enrolling in the NGENLA Copay Program.
  • Copay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “copay maximizer” programs).
  • Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or copay maximizer programs based on the availability of support under the NGENLA Copay Program and/or exclude the financial assistance provided under the offer NGENLA Copay Program from counting towards patient deductibles or out-of-pocket cost limitations.
  • Patients subject to an accumulator adjustment or copay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or copay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
  • Copay card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer at www.pfizerbridgecopay.com.
  • This copay card is not health insurance.
  • Offer good only in the U.S. (excluding Puerto Rico, the U.S. Virgin Islands, and Guam).
  • Copay card is limited to 1 per person during this offering period and is not transferable.
  • A copay card may not be redeemed more than once per 21 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  • Offer expires 12/31/2026.
  • For questions regarding the offer, please call 1-800-645-1280, visit www.NGENLA.com, or write NGENLA Copay Program, 430 Mountain Avenue, Suite 105, 
New Providence, NJ 07974
Pfizer Patient Assistance Program†

Assistance may be available for eligible uninsured patients or patients with public insurance who meet all other eligibility criteria.

Important Safety Information & Use

Important Safety
Information & Use

INDICATION
NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.
IMPORTANT SAFETY INFORMATION
Do not use NGENLA if:
  • your child has a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems.
  • your child is allergic to somatrogon-ghla or any of the ingredients in NGENLA.
  • your child has closed bone growth plates.
  • your child has cancer or other tumors.
  • your child’s healthcare provider tells you that your child has certain types of eye problems caused by diabetes.
  • your child has Prader-Willi syndrome, is severely obese, or has breathing problems including sleep apnea (briefly stopping breathing during sleep).
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
  • has had heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • has had a history of problems breathing while they slept.
  • has or has had cancer or any tumor.
  • has diabetes.
  • is pregnant or plans to become pregnant. It is not known if NGENLA will harm your child’s unborn baby. Talk to your child’s healthcare provider if your child is pregnant or plans to become pregnant.
  • is breastfeeding or plans to breastfeed. It is not known if NGENLA passes into breast milk. You and your child’s healthcare provider should decide if they will take NGENLA while breastfeeding.
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works.

NGENLA may cause serious side effects, including:
  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • serious allergic reactions. Get medical help right away if your child has the following symptoms: swelling of the face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in the chest, sweating.
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your child’s healthcare provider will need to monitor your child for a return of cancer or a tumor. Contact your child’s healthcare provider if your child starts to have headaches, or has changes in behavior, changes in vision, or changes in moles, birthmarks, or the color of the skin.
  • new or worsening high blood sugar or diabetes. Your child’s blood sugar may need to be monitored during treatment with NGENLA.
  • increase in pressure inside the skull. If your child has headaches, eye problems, nausea or vomiting, contact your child’s healthcare provider.
  • your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in the joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Fluid retention can happen in children during treatment with NGENLA. Tell your child’s healthcare provider if your child has any of these signs or symptoms of fluid retention.
  • decrease in a hormone called cortisol. Your child’s healthcare provider will do blood tests to check your child’s cortisol levels. Tell your child’s healthcare provider if your child has severe fatigue, dizziness, weakness, vomiting, dehydration, or weight loss.
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well NGENLA works. Your child’s healthcare provider will do blood tests to check your child’s hormone levels.
  • hip and knee pain or limp (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
  • worsening of curvature of the spine (scoliosis). If your child has scoliosis, your child will need to be checked often for an increase in the curve of the spine.
  • severe and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s healthcare provider if your child has any new abdominal pain.
  • loss of fat and tissue weakness in the area of skin you inject. Talk to your child’s healthcare provider about rotating the areas where you inject NGENLA.
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea.
  • increase in phosphorus, alkaline phosphatase and parathyroid hormone levels in the blood. Your child’s healthcare provider will do blood tests to check this.
The most common side effects (≥5%) of NGENLA include: injection site reactions (such as pain, swelling, rash, itching, bleeding), common cold, headache, fever, low red blood cells (anemia), cough, vomiting, decrease in thyroid hormone levels, stomach (abdominal) pain, rash, throat pain.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0599